DJ Spero Therapeutics Shares Fall After FDA Puts SPR720 Study on Hold >SPRO
By Colin Kellaher
Shares of Spero Therapeutics Inc. fell more than 20% on Friday after the U.S. Food and Drug Administration placed a clinical hold on the company's Phase 2a clinical trial of its SPR720 antibacterial agent.
Spero shares were recently down 21% to $14.99.
Spero, which is studying SPR720 for the treatment of patients with pulmonary infections due to nontuberculous mycobacteria, said it paused dosing of humans in the trial after observing deaths with inconclusive causality in non-human primates in a separate study.
The Cambridge, Mass., biopharmaceutical company said it is conducting the animal study to assess the potential toxicity of SPR720 over a four-month period.
Spero said it is working with FDA to evaluate whether the findings from the toxicology study are drug-related, and what impact, if any, the study may have on the SPR720 Phase 2a trial.
Write to Colin Kellaher at email@example.com
(END) Dow Jones Newswires
February 05, 2021 10:38 ET (15:38 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.